Welcome to our dedicated page for Celldex Therapeutics news (Ticker: CLDX), a resource for investors and traders seeking the latest updates and insights on Celldex Therapeutics stock.
Celldex Therapeutics, Inc. (NASDAQ: CLDX) generates frequent news as it advances antibody-based therapies in immunology, with a particular emphasis on mast cell–driven diseases. Company updates often center on barzolvolimab, a humanized monoclonal antibody targeting the KIT receptor on mast cells, and CDX-622, a bispecific antibody that neutralizes thymic stromal lymphopoietin (TSLP) and depletes mast cells via stem cell factor (SCF) starvation.
News coverage for Celldex commonly includes clinical trial milestones across multiple indications. For barzolvolimab, the company reports data from Phase 2 studies in chronic spontaneous urticaria (CSU) and chronic inducible urticarias such as cold urticaria (ColdU) and symptomatic dermographism (SD), describing statistically significant improvements in urticaria activity scores, provocation tests and quality-of-life measures, along with favorable safety profiles. Investors and clinicians can also follow announcements about the global Phase 3 EMBARQ-CSU program in CSU and the registrational Phase 3 EMBARQ-ColdU and SD program in ColdU and SD.
Additional Celldex news items highlight expansion of the barzolvolimab program into prurigo nodularis and atopic dermatitis, as well as strategic decisions such as discontinuing development in eosinophilic esophagitis (EoE) after a Phase 2 study showed mast cell depletion without clinical benefit. Updates on CDX-622 provide insight into early-stage safety, pharmacokinetics and pharmacodynamics, including sustained reductions in serum tryptase in healthy volunteers.
Corporate news may feature quarterly financial results, leadership appointments and participation in healthcare and investor conferences. For readers tracking CLDX, this news stream offers a view into Celldex’s progress in mast cell biology, the evolution of its clinical pipeline and key regulatory and financial disclosures. Bookmarking this page allows ongoing access to company-issued press releases and related market-relevant developments.
Celldex Therapeutics (NASDAQ:CLDX) announced positive interim results from the Phase 1b study of barzolvolimab in chronic spontaneous urticaria, showing significant symptom relief. The Phase 2 studies for chronic urticaria have commenced. Financially, total revenue dropped to $0.2 million in Q2 2022, down from $3.5 million in Q2 2021. R&D expenses surged to $20.7 million, influenced by clinical trial costs, while G&A expenses increased due to higher legal costs. The net loss reached $36.0 million, or ($0.77) per share. Despite the losses, the company maintains sufficient cash to fund operations through 2025.
Celldex Therapeutics (NASDAQ:CLDX) has commenced a Phase 2 clinical trial for barzolvolimab, targeting chronic inducible urticaria (CIndU), specifically cold urticaria and symptomatic dermographism. This double-blind, placebo-controlled study involves 180 patients and aims to assess the efficacy and safety of varied dosing regimens over 20 weeks. Preliminary Phase 1b data showed promising results, suggesting potential for significant improvement in treatment options for patients suffering from these conditions.
Celldex Therapeutics (NASDAQ:CLDX) has reported interim data from its ongoing Phase 1b trial of barzolvolimab, specifically targeting patients with moderate to severe chronic spontaneous urticaria (CSU). The study indicated a mean reduction in urticaria activity score (UAS7) of 66.6% at the 1.5 mg/kg dose and 75.1% at 3 mg/kg. A complete response (UAS7=0) was achieved by 57.1% and 44.4% of patients respectively. Notably, barzolvolimab exhibited a favorable safety profile, reinforcing its potential for Phase 2 studies.
Celldex Therapeutics (NASDAQ:CLDX) has initiated a Phase 2 clinical trial for barzolvolimab to treat chronic spontaneous urticaria (CSU), with the first patient dosed on June 21, 2022. This monoclonal antibody targets the receptor tyrosine kinase KIT and aims to provide new therapeutic options for CSU patients suffering from debilitating symptoms. The randomized study will include approximately 168 participants comparing different doses of barzolvolimab against a placebo over 16 weeks, followed by a 36-week treatment phase.
Celldex Therapeutics (NASDAQ:CLDX) announced the appointment of Cheryl L. Cohen and Dr. Garry Neil to its Board of Directors on June 16, 2022. Their extensive backgrounds in the pharmaceutical and biotechnology sectors are expected to support the company's clinical and corporate objectives. Cohen, previously Chief Commercial Officer of Medivation, brings commercialization experience, while Dr. Neil has held pivotal roles at various biotech firms and offers deep scientific expertise. This leadership addition aims to bolster Celldex's strategy as it advances its therapeutic pipeline.
Celldex Therapeutics (NASDAQ:CLDX) announced that its senior management will participate in a fireside chat at the 2022 Jefferies Global Healthcare Conference on June 8, 2022, at 8:30 a.m. ET in New York City. This event will provide insights into the company's advancements in monoclonal and bispecific antibodies aimed at treating severe diseases.
A webcast of the presentation will be accessible on the Investors & Media section of the Celldex website, with a replay available for 30 days afterward.
Celldex Therapeutics (NASDAQ:CLDX) announced the acceptance of an abstract detailing the Phase 1b study of barzolvolimab (CDX-0159) for patients with antihistamine refractory chronic spontaneous urticaria (CSU). This late-breaking electronic poster presentation will occur at the EAACI Annual Congress 2022 from July 1-3, 2022. The study aims to evaluate the safety and efficacy of multiple ascending doses in 40 patients who continue to experience symptoms despite antihistamine treatment. Results will include findings from various dosage cohorts.
Celldex Therapeutics (NASDAQ:CLDX) reported its Q1 2022 financial results, highlighting a net loss of $23.1 million ($0.49 per share), up from a loss of $16.5 million in Q1 2021. Total revenue decreased to $0.2 million from $0.7 million due to reduced services under agreements with Rockefeller University and Gilead Sciences. R&D expenses rose to $17.1 million, and G&A expenses increased to $6.9 million. The company remains on track with its clinical programs, including the Phase 1b study of barzolvolimab for chronic spontaneous urticaria, with a Phase 2 initiation expected this quarter.
Celldex Therapeutics (NASDAQ: CLDX) reported its 2021 financial results, highlighting a 95% complete response rate in its Phase 1b study for chronic inducible urticaria with CDX-0159. The firm holds $408.3 million in cash, sufficient to fund operations through 2025. Phase 2 studies for chronic spontaneous urticaria and eosinophilic esophagitis are set to begin in Q2 2022 and Q4 2022, respectively. However, total revenues dropped to $0.3 million in Q4 2021 compared to $3.8 million in Q4 2020, and the net loss for the year was $70.5 million.
Celldex Therapeutics (NASDAQ:CLDX) will host a conference call on February 28, 2022, at 4:30 p.m. ET to discuss its Q4 and full year 2021 financial results and corporate updates. Interested parties can access the live or recorded webcast on the company's website. Celldex focuses on developing monoclonal and bispecific antibodies targeting serious diseases with inadequate treatments. Their pipeline aims to enhance patient outcomes in cancer and inflammatory diseases.